Q2 2026 revenue rose 32% year-over-year to $256.1 million, with strong growth in both endocrinology and oncology. LIFYORLI's launch drove $47.6 million in first-quarter sales and rapid adoption, while guidance was raised to $1.1–$1.2 billion for 2026.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.